October 2010 Briefing - RheumatologyLast Updated: November 01, 2010.
Here are what the editors at HealthDay consider to be the most important developments in Rheumatology for October 2010. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that are the most likely to affect clinical practice.
FDA: Methotrexate Injection Vials Recalled
FRIDAY, Oct. 29 (HealthDay News) -- The U.S. Food and Drug Administration and Sandoz have notified health care professionals of a voluntary recall of 24 lots of methotrexate injection (50 mg/2 mL and 250 mg/10 mL vials) due to the presence of small glass particulates in a limited number of vials in four lots.
Primary Care Trails Other Specialties in Hourly Wages
TUESDAY, Oct. 26 (HealthDay News) -- Primary care physicians have substantially lower hourly wages than other specialists, and although most physicians find Medicare reimbursement inequitable, they show little consensus on how to reform it, according to two studies published in the Oct. 25 issue of the Archives of Internal Medicine.
Cortisone May Help Tennis Elbow in Short Term
FRIDAY, Oct. 22 (HealthDay News) -- Cortisone injections may provide better short-term relief from tennis elbow than other treatments, but the results don't last beyond three to six weeks, according to research published online Oct. 22 in The Lancet.
Risk of Restless Legs Found Higher in Fibromyalgia Patients
WEDNESDAY, Oct. 20 (HealthDay News) -- Individuals with fibromyalgia appear to have a substantially higher risk of restless legs syndrome (RLS), according to research published in the Oct. 15 issue of the Journal of Clinical Sleep Medicine.
Spinal Fractures Spotlighted During World Osteoporosis Day
WEDNESDAY, Oct. 20 (HealthDay News) -- Spinal fractures worldwide occur at an estimated rate of one every 22 seconds, and health care professionals need to be able to recognize the signs of these fractures in their patients, according to the International Osteoporosis Foundation (IOF) report, The Breaking Spine.
Expectations Don't Predict Recovery Time for All Injuries
FRIDAY, Oct. 15 (HealthDay News) -- Recovery expectations appear to predict future recovery among workers filing injury claims for back pain but not for those filing claims for other musculoskeletal conditions, according to a study published in the October issue of the Journal of Spinal Disorders & Techniques.
Fibromyalgia Sufferers May Benefit From Yoga Practice
THURSDAY, Oct. 14 (HealthDay News) -- Yoga might provide an effective counterpart to pharmacotherapy in helping patients cope with and manage fibromyalgia, according to research published in the November issue of Pain.
Older Women at Fracture Risk in Spinal Instrumentation Surgery
TUESDAY, Oct. 12 (HealthDay News) -- Postmenopausal women who have spinal fusion with instrumentation are at risk of developing fractures at other nearby vertebrae, usually within two years of the surgery, according to a study in the Oct. 1 issue of Spine.
Arthritis Prevalence Nearly 25 Percent in U.S. Adults
FRIDAY, Oct. 8 (HealthDay News) -- Nearly a quarter of U.S. adults have doctor-diagnosed arthritis and many also have arthritis-attributable activity limitation (AAAL); the prevalence of arthritis is particularly high among obese individuals, according to a report published in the Oct. 8 issue of the U.S. Centers for Disease Control and Prevention's Morbidity and Mortality Weekly Report.
Abatacept Found Ineffective for Non-Life-Threatening Lupus
THURSDAY, Oct. 7 (HealthDay News) -- In patients with non-life-threatening systemic lupus erythematosus (SLE), abatacept fails to prevent new flares and has a nearly one-in-five rate of serious adverse events (SAEs), according to a study in the October issue of Arthritis & Rheumatism.
DMARDs, Glucocorticoids, Biologics Similar for RA
FRIDAY, Oct. 1 (HealthDay News) -- Treatment of rheumatoid arthritis (RA) with disease-modifying antirheumatic drugs (DMARDs), glucocorticoids, biologics, or a combination of these agents significantly reduces radiographic evidence of joint destruction, with no advantage seen for patients whose treatment includes biologics, according to research published in the October issue of Arthritis & Rheumatism.
FDA Calls for Halt on Marketing of Unapproved Colchicine
FRIDAY, Oct. 1 (HealthDay News) -- The U.S. Food and Drug Administration has ordered companies manufacturing, distributing, or marketing unapproved single-ingredient oral colchicine to cease doing so.
|Previous: October 2010 Briefing - Pulmonology||Next: October 2010 Briefing - Surgery|
Reader comments on this article are listed below. Review our comments policy.